Final

<p align="justify">TEL AVIV, May 28, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that multiple abstracts across its oral peptide pipeline have been accepted for presentation at ENDO 2026, the annual meeting of the Endocrine Society, taking place June 13-16, 2026 in Chicago, Illinois, USA. Notably, new clinical data supporting Entera’s single EB613 tablet as the final candidate for its planned Phase 3 study in postmenopausal women with osteoporosis was selected for a Late Breaking Oral Presentation.</p>

May 28, 2026

<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTE9WWFpMaHVodEltOVhScjM4QUlBN3l1UThTYkE4dUVrQ2xObGVCY0FaRGZpMzlvQWJpM2xBMFFxQTQ0YXBYVi1PMkluYWhfQVFGMXE1bFYzNURaUUkyUVJxSmE5ODV6Zm8?oc=5" target="_blank">Imperva Israel GM exits as Thales finalizes cyber merger</a>&nbsp;&nbsp;<font color="#6f6f6f">CTech</font>

Nov 2, 2025